Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in Rheumatology 2020-06, Vol.60 (1), p.32-11, Article 32
Hauptverfasser:	Dos Reis Neto, Edgard Torres, Kakehasi, Adriana Maria, de Medeiros Pinheiro, Marcelo, Ferreira, Gilda Aparecida, Marques, Cláudia Diniz Lopes, da Mota, Licia Maria Henrique, Dos Santos Paiva, Eduardo, Pileggi, Gecilmara Cristina Salviato, Sato, Emília Inoue, Reis, Ana Paula Monteiro Gomides, Xavier, Ricardo Machado, Provenza, José Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-inflammatory agents Antimalarial agents Antimalarials Antimalarials - pharmacology Antiphospholipid Syndrome - drug therapy Antiphospholipid Syndrome - immunology Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology B cells Care and treatment Chloroquine Chloroquine - pharmacology Chronic immune-mediated inflammatory rheumatic diseases Coronavirus Infections - drug therapy Coronaviruses COVID-19 Cytokines Disease Diseases Drug dosages Drug Eruptions - etiology Drug Interactions Epidemics Female Glucose - metabolism Heart Diseases - chemically induced Humans Hydroxychloroquine Hydroxychloroquine - pharmacology Hypertension Immunity Immunomodulation Immunosuppressive agents Lipids - blood Lupus Lupus erythematosus Lupus Erythematosus, Cutaneous - drug therapy Lupus Erythematosus, Cutaneous - immunology Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - mortality Male Metabolism Mortality Pandemics Patient monitoring equipment Platelet Aggregation - drug effects Pneumonia, Viral - drug therapy Position and Guidelines Pregnancy Renal Insufficiency - prevention & control Retinal Diseases - chemically induced Retirement benefits Rheumatic diseases RHEUMATOLOGY Sjogren's Syndrome - drug therapy Sjogren's Syndrome - immunology Systemic lupus erythematosus T cell receptors Time
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.
ISSN:	2523-3106 2523-3106
DOI:	10.1186/s42358-020-00134-8